NO942360L - Vaccine and polypeptides useful for this - Google Patents

Vaccine and polypeptides useful for this

Info

Publication number
NO942360L
NO942360L NO942360A NO942360A NO942360L NO 942360 L NO942360 L NO 942360L NO 942360 A NO942360 A NO 942360A NO 942360 A NO942360 A NO 942360A NO 942360 L NO942360 L NO 942360L
Authority
NO
Norway
Prior art keywords
xaa
vaccine
xaa2
gly
polypeptides useful
Prior art date
Application number
NO942360A
Other languages
Norwegian (no)
Other versions
NO942360D0 (en
Inventor
Andrew Richard Milner
Michael Panaccio
Terence William Spithill
Gene Louise Wijffels
Original Assignee
Daratech Proprietary Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daratech Proprietary Ltd filed Critical Daratech Proprietary Ltd
Publication of NO942360D0 publication Critical patent/NO942360D0/no
Publication of NO942360L publication Critical patent/NO942360L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptider oppnåelige fra en art av Fasciola omfattende den følgende sekvens: Gln-Xaa-Xaa-Xaa-Xaa1-Xaa-Cys-Trp-Xaa-Xaa-Xaa2 hvori Xaa er en hvilken som helst aminosyre, Xaaj er Gly eller Glu og Xaa2 er Ser, Thr, Ala eller Gly er omtalt. Der omtales også vaksiner og fremgangsmåter for behandling for å redusere spredningen av infeksjon av leverikte og DNA-sekvenser av polypeptidene.Peptides obtainable from a species of Fasciola comprising the following sequence: Gln-Xaa-Xaa-Xaa-Xaa1-Xaa-Cys-Trp-Xaa-Xaa-Xaa2 wherein Xaa is any amino acid, Xaaj is Gly or Glu and Xaa2 is Ser, Thr, Ala or Gly are discussed. Also mentioned are vaccines and methods of treatment to reduce the spread of infection of liver tissue and DNA sequences of the polypeptides.

NO942360A 1993-02-05 1994-06-21 Vaccine and polypeptides useful for this NO942360L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL710993 1993-02-05
PCT/AU1994/000051 WO1994017820A1 (en) 1993-02-05 1994-02-04 Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same

Publications (2)

Publication Number Publication Date
NO942360D0 NO942360D0 (en) 1994-06-21
NO942360L true NO942360L (en) 1994-10-05

Family

ID=3776688

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942360A NO942360L (en) 1993-02-05 1994-06-21 Vaccine and polypeptides useful for this

Country Status (8)

Country Link
EP (1) EP0647138A4 (en)
JP (1) JPH07505787A (en)
AU (1) AU5996294A (en)
BR (1) BR9404004A (en)
CA (1) CA2126455A1 (en)
NO (1) NO942360L (en)
NZ (1) NZ261279A (en)
WO (1) WO1994017820A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721466A1 (en) * 1993-09-28 1996-07-17 The University Of Melbourne Protective antigens against parasites
BR9808251B1 (en) * 1997-03-11 2012-09-04 vaccine, and use of an isolated or recombinant protein or antigenic fragment thereof.
WO2002038744A2 (en) * 2000-10-18 2002-05-16 Incyte Genomics, Inc. Proteases
HUE033623T2 (en) 2002-09-11 2017-12-28 Genentech Inc Protein purification
PL201419B1 (en) * 2002-12-04 2009-04-30 Inst Biotechnologii I Antybiot Chimeric protein, sequence, construction, vegetable cell, method of obtaining chimeric protein and transgenic plant, transgenic plant, application of transgenic plant and chimeric protein
PL196114B1 (en) * 2002-12-31 2007-12-31 Inst Biotechnologii I Antybiot Inclusion bodies as antigenes in oral immunization of animals
MX2012004133A (en) * 2009-10-07 2012-05-08 Wyeth Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof.
ES2525106B1 (en) * 2013-06-17 2015-09-29 Universidad De Salamanca Synthetic peptide derived from Fasciola hepatica and its use as a vaccine
GB201714057D0 (en) * 2017-09-01 2017-10-18 Univ College Dublin Nat Univ Of Ireland Dublin A fasciola hepatica antigen and vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8432401D0 (en) * 1984-12-21 1985-02-06 Bennett C E Liver fluke antigens
AU7871987A (en) * 1986-08-18 1988-03-08 Australian National University, The Helminth parasite vaccine
JPH04507235A (en) * 1989-01-31 1992-12-17 ダラテック　ピーテーワイ　リミテッド Vaccines for prophylactic treatment against liver fluke infections in ruminants
JP2700088B2 (en) * 1991-07-25 1998-01-19 房則 濱島 Immunosuppressants
ES2199947T3 (en) * 1992-10-21 2004-03-01 John Pius Dalton VACCINE CONTAINING A TIOLPROTEASE.

Also Published As

Publication number Publication date
EP0647138A1 (en) 1995-04-12
JPH07505787A (en) 1995-06-29
CA2126455A1 (en) 1994-08-06
EP0647138A4 (en) 1996-03-06
BR9404004A (en) 1999-05-25
WO1994017820A1 (en) 1994-08-18
AU5996294A (en) 1994-08-29
NO942360D0 (en) 1994-06-21
NZ261279A (en) 1996-03-26

Similar Documents

Publication Publication Date Title
NL300013I1 (en) New protein with TNF-inhibiting effect and their ber
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
EP2019118B1 (en) Method for synthesizing thymosins
MX9703643A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
HUP0302965A2 (en) Vaccine
IE63547B1 (en) Anticoagulant peptides
DE69435075D1 (en) , THE SIGNAL SEPENSE PEPTIDES OF THE ENDOPLASMATIC RETICULUM AND AT LEAST ONE OTHER PEPTIDE, THEIR USE IN VACCINES AND THE TREATMENT OF DISEASES
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
TR199802534T2 (en) Leptin (OB Protein) fragmanlar�
ATE314083T1 (en) PEPTIDES CONTAINING LYSINE FOR THE TREATMENT OF HEART DISEASE
NO942360L (en) Vaccine and polypeptides useful for this
NO941151L (en) Linear adhesion inhibitors
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
JP2916164B2 (en) Anticoagulant peptide alcohols
DE69508382D1 (en) PEPTOMERS WITH INCREASED IMMUNOGENICITY
AU630132B2 (en) Anticoagulant peptides
US5541161A (en) Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin
DE69330268T2 (en) HEMOREGULATING PEPTIDES
JPH03120297A (en) Anticoagulant peptide
NO975565L (en) Leg stimulating factor
ES2176334T3 (en) THE USE OF GABAPENTIN IN THE TREATMENT OF ANXIETY AND PANIC.
DE3782880T2 (en) INHIBITIVE PEPTIDES.
RU95120588A (en) CYCLOGEXAEPEPTIDES, THEIR MIXTURES, METHOD FOR PRODUCING AND USING THEM
US5789540A (en) Anticoagulant peptides
DK0811067T3 (en) Equine arteritis virus peptides, antibodies and their use in a diagnostic test